HPX

Hemopexin (HPX) is a plasma glycoprotein that functions as the primary extracellular scavenger of free heme, preventing heme-driven Fenton-chemistry oxidative damage and enabling hepatocyte iron salvage. HPX is a single-chain, two-domain β-propeller protein (439 residues, six disulfide bridges) whose heme binding induces a conformational change at the inter-domain hinge, and the heme–HPX complex is internalized by hepatocytes via LRP-1/LRP-2 receptor-mediated endocytosis (PMID:3855550, PMID:12042069, PMID:17185359). HPX also physically associates with apoA-1-containing HDL particles in a haptoglobin-dependent manner, and this association modulates HDL inflammatory properties in atherosclerotic settings (PMID:19433579). Overexpression of HPX suppresses MAPK signaling and hepatocellular carcinoma cell proliferation in vitro and in vivo, indicating an additional role as a negative regulator of mitogenic signaling (PMID:40858030).

1. 1985 High

   Determination of the complete primary structure of HPX established its two-domain architecture arising from gene duplication and demonstrated that heme binding induces a conformational change at the inter-domain hinge, providing the first structural framework for understanding heme–HPX interaction.

   Evidence Complete protein sequencing (Edman degradation, tryptic peptide mapping) and limited proteolysis of apo- vs. heme-saturated HPX

   PMID:3855550

   Open questions at the time

   • Atomic-resolution crystal structure of the heme–HPX complex was not yet available
   • Identity of the hepatocyte receptor for heme–HPX complex was unknown
   • Stoichiometry and thermodynamics of heme binding were not precisely defined in this study
2. 2002 High

   Consolidation of binding, uptake, and knockout studies established that HPX possesses the highest heme-binding affinity among plasma proteins and functions primarily as an antioxidant scavenger—not merely an iron transport protein—by delivering heme to hepatocytes via receptor-mediated endocytosis.

   Evidence Integration of binding affinity measurements, cell-based heme uptake assays, and HPX-knockout mouse phenotyping

   PMID:12042069

   Open questions at the time

   • Molecular identity of the hepatocyte receptor had been proposed but receptor-specific knockdown was not yet shown
   • Intracellular signaling events triggered upon heme–HPX endocytosis were incompletely mapped
3. 2006 Medium

   Identification of LRP-1 (CD91) and LRP-2 (megalin) as the endocytic receptors for heme–HPX resolved the receptor question and revealed that the four-bladed β-propeller HPX domain is a conserved scaffold used across diverse proteins for ligand-receptor interactions.

   Evidence Domain structural analysis and receptor-binding assays with LRP-1/LRP-2

   PMID:17185359

   Open questions at the time

   • Relative contributions of LRP-1 vs. LRP-2 to hepatocyte heme uptake in vivo were not dissected
   • Whether HPX is recycled or degraded after receptor-mediated endocytosis remained debated
4. 2009 Medium

   Discovery of HPX's physical association with HDL particles in a haptoglobin-dependent manner expanded the functional repertoire of HPX beyond heme scavenging, linking it to HDL inflammatory remodeling in atherosclerosis.

   Evidence Co-immunoprecipitation and HDL protein analysis in apoE−/− and Hp−/− mouse models and human coronary heart disease patients; apoA-1 mimetic peptide dissociation experiments

   PMID:19433579

   Open questions at the time

   • Direct binding interface between HPX and apoA-1 or other HDL components was not mapped
   • Whether HPX modifies HDL function independently of hemoglobin/haptoglobin cargo was unclear
   • Causal contribution of HPX–HDL association to atherogenesis was not tested in HPX-knockout models
5. 2025 Medium

   Functional studies in hepatocellular carcinoma revealed that HPX negatively regulates MAPK signaling, suppressing tumor cell proliferation, migration, and drug resistance, extending HPX's biology into cancer-relevant pathways.

   Evidence HPX overexpression in HCC cell lines with Western blot for MAPK pathway components and in vivo mouse xenograft validation

   PMID:40858030

   Open questions at the time

   • Direct molecular target through which HPX inhibits MAPK activation was not identified
   • Whether this anti-tumor effect is heme-binding-dependent or independent was not tested
   • Findings have not been replicated in independent cohorts or labs

• Key unresolved questions include the precise mechanism by which HPX engages the Nrf2/HO-1 antioxidant axis, whether HPX's roles in MAPK suppression and HDL remodeling are mechanistically linked to its heme-binding function, and the structural basis for receptor selectivity between LRP-1 and LRP-2.
• HPX–Nrf2 pathway placement relies on proteomics and docking without direct interaction validation
• No structure of full-length HPX in complex with LRP-1 or LRP-2 exists
• Heme-binding-dependent vs. -independent functions of HPX have not been systematically dissected